IGNITE Program

Innovation Grants to Nurture Initial Translational Efforts (IGNITE)

A suite of early-stage therapy development funding programs called Innovation Grants to Nurture Initial Translational Efforts (IGNITE) is meant to serve a feeder program to the later-stage therapy development programs such as the Cooperate Research to Enable and Advance Translational Enterprises (CREATE) for Biologics and Blueprint Neurotherapeutics (BPN) Programs.

IGNITE program applications will be reviewed within the NINDS Scientific Review Branch and not at the Center for Scientific Review (CSR).

Definitions for Key Terms

Application Support Library-IGNITE Example: Milestones

Comparison of IGNITE Programs

Use this chart to help you decide which program better suits your needs.

Grant Program Entry Criteria End Goal Time Budget Limit

PAR-18-762: Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Rationally selected assay(s) and therapeutic agents

Testing funnel to triage candidates, a battery of assays and starting agents that are well profiled

3 years total for both R61 and R33 stages, with no more than 2 years in either stage.

Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $499,000 in direct costs in any single year.

PAR-18-761: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Evidence of validated/characterized animal model and PD measure, testing protocol and therapeutic agents

Well-characterized early-stage agents suitable for optimization

3 years total for both R61 and R33 stages, with no more than 2 years in either stage.

Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $499,000 in direct costs in any single year.

PAR-18-763: Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

Translational rationale for the proposed model system or pharmacodynamic marker and evidence of value for future drug discovery/development

Translationally relevant animal models, ex vivo systems, testing paradigms, and endpoints

3 years total for both R61 and R33 stages, with no more than 2 years in either stage.

Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $499,000 in direct costs in any single year.